About 30 results found for searched term "G-36" (0.055 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1645 | AG14361 | PARP |
| AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM. | ||
| M1658 | Axitinib | VEGFR/PDGFR |
| AG-013736 | ||
| Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. | ||
| M1719 | GSK461364 | PLK |
| GSK461364A | ||
| GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. | ||
| M1758 | Foretinib | c-Met |
| GSK089; EXEL-2880; XL880; GSK1363089 | ||
| Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. | ||
| M1855 | Dabrafenib Mesylate | Raf |
| GSK-2118436B | ||
| Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. | ||
| M1988 | Dabrafenib | Raf |
| GSK2118436 | ||
| Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. | ||
| M2050 | GSK2636771 | PI3K |
| GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. | ||
| M2269 | Tigecycline | Antibiotic |
| Tygacil, GAR-936 | ||
| Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL. | ||
| M2741 | GW843682X | PLK |
| GW843682 | ||
| GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. | ||
| M3835 | Alirocumab | PCSK9 |
| REGN 727；SAR 236553 | ||
| Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia. | ||
| M4382 | Artemisinine | Akt |
| Qinghaosu; NSC 369397 | ||
| Artemisinin (Qinghaosu) is a kind of sesquiterpene lactone, an antimalarial drug isolated from the aboveground part of Artemisia annua L. Artemisinin inhibits AKT signaling by decreasing pAKT in a dose-dependent manner. Artemisinin can reduce the proliferation, migration, invasion, tumorigenesis and metastasis of cancer cells, and Artemisinin has neuroprotective effects. | ||
| M4931 | Rucaparib | PARP |
| AG014699; PF-01367338 | ||
| Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains. | ||
| M5267 | E7449 | PARP |
| Stenoparib; 2X-121; MGI25036 | ||
| E7449 is an orally bioavailable, brain penetrable, small molecule dual inhibitor of PARP1/2 that also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1/2), important regulators of canonical Wnt/β-catenin signaling. It has IC50 values of 1.0 and 1.2 nM for PARP1 and 2, respectively. | ||
| M5269 | GSK180736A | ROCK |
| GSK180736 | ||
| GSK180736A, developed as a Rho-associated, coiled-coil-containing protein kinase inhibitor, binds to GRK2(G protein-coupled receptor kinase 2) with logIC50 pf -6.6 (logIC50 -4.0 for GRK5 and >-3 for GRK1); ≥400-fold selective for GRK2 over both GRK1 and GRK5. | ||
| M5398 | Aliskiren Hemifumarate | Renin |
| CGP 60536; CGP60536B; SPP 100 | ||
| Aliskiren hemifumarate is a direct renin inhibitor with IC50 of 1.5 nM. | ||
| M5723 | Lacidipine | Calcium Channel |
| GX-1048,GR-43659X,SN-305 | ||
| Lacidipine is a L-type calcium channel blocker, used for treating high blood pressure. | ||
| M6161 | GSK369796 Dihydrochloride | Potassium Channel |
| GSK369796 shows antimalerial activity with IC50 values of 11.2 nM for 3D7 strain, 12.6 nM for HB3 strain, 17.6 nM for K1 strain. | ||
| M6583 | CGP 36216 hydrochloride | Others |
| CGP 36216 hydrochloride is a gABA B antagonist; displays activity at presynaptic receptors. | ||
| M6740 | G-36 | Others |
| G-36 is a selective GPER antagonist. | ||
| M6764 | GR 79236 | Others |
| GR 79236 is a a 1 agonist. | ||
| M6780 | GYKI 53655 hydrochloride | Others |
| GYKI 53655 hydrochloride is a non-competitive AMPA receptor antagonist. | ||
| M8360 | CGP36742 | Others |
| CGP36742 was the first orally active GABAB-selective antagonist. | ||
| M9023 | Ellipticine | Topoisomerase |
| CCG36483; NSC71795 | ||
| Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor. | ||
| M9441 | GSK656 HCl | Anti-infection |
| GSK3036656; GSK070 hydrochloride | ||
| GSK656 is a potent Mtb LeuRS inhibitor, shows potent inhibition of Mtb LeuRS (IC50 = 0.20 μM) and in vitro antitubercular activity (Mtb H37Rv MIC = 0.08 μM). | ||
| M10180 | GW627368X | Prostaglandin Receptor |
| GW 627368 | ||
| GW627368X is a novel, potent and selective competitive antagonist of prostanoid EP4 receptors with additional human TP receptor affinity. | ||
| M10528 | GSK3685032 | DNA Methyltransferase |
| GSK3685032 is a potent first-in-class DNMT1-selective inhibitor. | ||
| M10637 | GSK3368715 2HCl | PRMTs |
| EPZ019997 2HCl | ||
| GSK3368715 2HCl is a novel potent, orally active, reversible type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50 values of 3.1 nM, 48 nM, 1148 nM, 5.7 nM and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6, PRMT8, respectively. | ||
| M10646 | GRP-60367 | Anti-infection |
| GRP-60367 is a first-in-class potent and selective inhibitor of rabies virus (RABV) entry that specifically targets the RABV G protein. | ||
| M10689 | ML224 | TSH Receptor |
| NCGC00242364; ANTAG3 | ||
| ML224 (NCGC00242364; ANTAG3) is a thyroid-stimulating hormone receptor TSHR counter-agonist with an IC50 of 2.1uM. | ||
| M10776 | AG-636 | DHODH |
| AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor,IC50 17 nM. AG-636 has strong anti-cancer effects. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
